MCID: OVR040
MIFTS: 13

Ovarian Clear Cell Cystadenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Clear Cell Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Clear Cell Cystadenocarcinoma:

Name: Ovarian Clear Cell Cystadenocarcinoma 12 71

Classifications:



External Ids:

Disease Ontology 12 DOID:7438
NCIt 49 C7980
UMLS 71 C0279667

Summaries for Ovarian Clear Cell Cystadenocarcinoma

Disease Ontology : 12 An ovarian cystadenocarcinoma that is characterized by the presence of cells with clear cytoplasm.

MalaCards based summary : Ovarian Clear Cell Cystadenocarcinoma The drugs Cisplatin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, t cells and bone marrow.

Related Diseases for Ovarian Clear Cell Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Clear Cell Cystadenocarcinoma

Drugs & Therapeutics for Ovarian Clear Cell Cystadenocarcinoma

Drugs for Ovarian Clear Cell Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
2
Bevacizumab Approved, Investigational Phase 3 216974-75-3
3
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
4
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
7 Angiogenesis Inhibitors Phase 3
8 Antineoplastic Agents, Immunological Phase 3
9 Tubulin Modulators Phase 2, Phase 3
10 Antimitotic Agents Phase 2, Phase 3
11 Albumin-Bound Paclitaxel Phase 2, Phase 3
12 Immunologic Factors Phase 3
13 Alkylating Agents Phase 3
14 Immunosuppressive Agents Phase 3
15 Antirheumatic Agents Phase 3
16 Analgesics Phase 3
17
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
18
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
19
Lenograstim Approved, Investigational Phase 2 135968-09-1
20
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
21
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
22
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
23
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
24
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
25
Liposomal doxorubicin Phase 2 31703
26 Anti-Bacterial Agents Phase 2
27 Antibiotics, Antitubercular Phase 2
28 topoisomerase I inhibitors Phase 2
29 Anti-Infective Agents Phase 2
30 Antifungal Agents Phase 2
31
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
32 Protein Kinase Inhibitors Phase 1, Phase 2
33 Antimetabolites Phase 2
34
Thiotepa Approved, Investigational Phase 1 52-24-4 5453
35
Melphalan Approved Phase 1 148-82-3 460612 4053
36
Iodine Approved, Investigational Phase 1 7553-56-2 807
37
Pancrelipase Approved, Investigational Phase 1 53608-75-6
38
Etoposide Approved Phase 1 33419-42-0 36462
39
Veliparib Investigational Phase 1 912444-00-9 11960529
40 Immunotoxins Phase 1
41 Adjuvants, Immunologic Phase 1
42 Interleukin-12 Phase 1
43 Vaccines Phase 1
44 Antibodies Phase 1
45 Antibodies, Monoclonal Phase 1
46 Immunoglobulins Phase 1
47 pancreatin Phase 1
48 Immunoglobulins, Intravenous Phase 1
49 Liver Extracts Phase 1
50 Endothelial Growth Factors Phase 1

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
2 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
3 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
6 A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
7 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
8 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
9 A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
10 LAPAROSCOPIC STAGING IN PATIENTS WITH INCOMPLETELY STAGED CANCERS OF THE OVARY Completed NCT00002538 Phase 2
11 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
12 A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
13 Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
14 A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
15 A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy Completed NCT00993655 Phase 2 carboplatin;cisplatin;paclitaxel
16 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
17 A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum Terminated NCT00354601 Phase 2 capecitabine;docetaxel
18 A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
19 A Phase I Trial of Combination Carboplatin and Lipsomal Doxorubicin (Doxil) In Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
20 A Phase I Study of Sequential Prolonged Oral Topotecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
21 A Phase I Study of Paclitaxel, Carboplatin, and Increasing Doses of Doxil in Untreated Ovarian, Peritoneal, and Tubal Carcinoma Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
22 A Phase I Trial of Melphalan and Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With a Complete Response Following Standard Therapy for Stage III/IV Epithelial Ovarian Cancer Completed NCT00002977 Phase 1 melphalan;thiotepa
23 A PHASE I TRIAL OF HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH PLATINUM-SENSITIVE, CHEMOTHERAPY-RESPONSIVE EPITHELIAL OVARIAN CARCINOMA Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
24 Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing Completed NCT00066651 Phase 1
25 A Phase I Study of Intraperitoneal Egen-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Pegylated Liposomal-Doxorubicin (PLD, Doxil (NSC# 712227 or Lipodox (NSC#673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01489371 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride
26 Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Completed NCT00408590 Phase 1
27 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
28 Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days Completed NCT00006981 Phase 1
29 A Phase I Feasibility Trial of Carboplatin and Topotecan Followed by Carboplatin and Paclitaxel (Sequential Doublets) in Patients With Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
30 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
31 A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT01459380 Phase 1 Carboplatin;Pegylated Liposomal Doxorubicin Hydrochloride;Veliparib
32 A Phase I Study of Liposomal Doxorubicin (Doxil) and Prolonged Etoposide As Second Line Therapy in Ovarian, Tubal and Peritoneal Carcinoma Terminated NCT00003380 Phase 1 etoposide;pegylated liposomal doxorubicin hydrochloride
33 Pelvic Mass Study to Develop Serum Proteomic Profiles (SIGNATURES) for Epithelial Ovarian Cancer Diagnosis and Prognosis Unknown status NCT00238342
34 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Unknown status NCT00897039
35 Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol Terminated NCT00904514

Search NIH Clinical Center for Ovarian Clear Cell Cystadenocarcinoma

Genetic Tests for Ovarian Clear Cell Cystadenocarcinoma

Anatomical Context for Ovarian Clear Cell Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Clear Cell Cystadenocarcinoma:

40
Ovary, T Cells, Bone Marrow, Bone, Liver, Testes, Endothelial

Publications for Ovarian Clear Cell Cystadenocarcinoma

Variations for Ovarian Clear Cell Cystadenocarcinoma

Expression for Ovarian Clear Cell Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Clear Cell Cystadenocarcinoma.

Pathways for Ovarian Clear Cell Cystadenocarcinoma

GO Terms for Ovarian Clear Cell Cystadenocarcinoma

Sources for Ovarian Clear Cell Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....